Global collaborative networks on meta-analyses of randomized trials published in high impact factor medical journals: a social network analysis by Catalá-López, Ferrán et al.
Catalá-López et al. BMC Medicine 2014, 12:15
http://www.biomedcentral.com/1741-7015/12/15RESEARCH ARTICLE Open AccessGlobal collaborative networks on meta-analyses of
randomized trials published in high impact factor
medical journals: a social network analysis
Ferrán Catalá-López1,2*, Adolfo Alonso-Arroyo3,4, Brian Hutton5, Rafael Aleixandre-Benavent3 and David Moher5Abstract
Background: Research collaboration contributes to the advancement of knowledge by exploiting the results of
scientific efforts more efficiently, but the global patterns of collaboration on meta-analysis are unknown. The purpose
of this research was to describe and characterize the global collaborative patterns in meta-analyses of randomized trials
published in high impact factor medical journals over the past three decades.
Methods: This was a cross-sectional, social network analysis. We searched PubMed for relevant meta-analyses of
randomized trials published up to December 2012. We selected meta-analyses (including at least randomized trials as
primary evidence source) published in the top seven high impact factor general medical journals (according to Journal
Citation Reports 2011): The New England Journal of Medicine, The Lancet, the BMJ, JAMA, Annals of Internal Medicine,
Archives of Internal Medicine (now renamed JAMA Internal Medicine), and PLoS Medicine. Opinion articles, conceptual
papers, narrative reviews, reviews without meta-analysis, reviews of reviews, and other study designs were excluded.
Results: Overall, we included 736 meta-analyses, in which 3,178 authors, 891 institutions, and 51 countries participated.
The BMJ was the journal that published the greatest number of articles (39%), followed by The Lancet (18%), JAMA
(15%) and the Archives of Internal Medicine (15%). The USA, the UK, and Canada headed the absolute global productivity
ranking in number of papers. The 64 authors and the 39 institutions with the highest publication rates were identified.
We also found 82 clusters of authors (one group with 55 members and one group with 54 members) and 19 clusters
of institutions (one major group with 76 members). The most prolific authors were mainly affiliated with the University
of Oxford (UK), McMaster University (Canada), and the University of Bern (Switzerland).
Conclusions: Our analysis identified networks of authors, institutions and countries publishing meta-analyses of
randomized trials in high impact medical journals. This valuable information may be used to strengthen scientific
capacity for collaboration and to help to promote a global agenda for future research of excellence.
Keywords: Authorship, Evidence-based medicine, Meta-analysis, Randomized controlled trial, Scientific
collaboration, Social network analysisBackground
The past decades have seen the establishment of evidence
synthesis, particularly systematic reviews and meta-analyses,
as a key component of evidence based medicine (EBM)
[1,2]. Meta-analyses of randomized trials have become
more widely accepted by clinicians, researchers and policy
makers as a useful tool to critically assess the totality of* Correspondence: ferran_catala@hotmail.com
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article, unless otherwise stated.evidence in a research question. When performed well and
reported completely, incorporating explicit and detailed
methods and results, such studies produce information
that can have undoubtedly major, immediate effects on
medical practice, research agendas and the establishment
of healthcare policies.
Important milestones that may have encouraged research
in this field, from the point of view of scientific publications
and institutional development of EBM [1-4], include the
creation of international research groups, centers, and con-
sortia (such as the Centre for Evidence Based Medicine andentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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to groups developing reporting guidelines to ensure arti-
cles contain all essential information, such as QUOROM
(Quality of Reporting of Meta-analyses) [5] and, more re-
cently, PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) [6].
Global health challenges require research collaboration
and multi-lateral programs on a global scale, owing to
the nature and magnitude of the public health problems.
Noteworthy examples include major environmental, polit-
ical, and social determinants of health, as well as complex
and changing clinical issues related to the conditions and
risk factors that cause the highest burden of disease around
the world [7-9]. Despite continuous efforts of individual
scientists and institutions to remedy deficiencies in health-
care effectiveness and safety, multiple gaps and disparities
remain. Research collaboration contributes to the advance-
ment of knowledge by exploiting the results of scientific
efforts more efficiently, but the global patterns of collabor-
ation on meta-analysis are unknown. Given that meta-
analyses can provide high-quality clinical evidence regarding
the robustness of the effects of healthcare interventions
to inform medical practice, there is an urgent need to
evaluate and promote scientific activity and growth in the
field of EBM [4,10-12].
Social network analysis [13], the study of structure
derived from the regularities in the patterning of relation-
ships between social entities (which might be people or
organizations), is grounded in the assessment of empirical
data, and can provide an appropriate approach to identify
top scientists and researchers, groups of excellence, and
leading institutions. It also offers information to assess
the citation patterns among papers within a specialty
[14], to identify gaps in the evidence from scientific re-
search [15], and to understand the structure and nature of
relationships and interactions within a scientific community
that collaborate to better achieve common or compatible
goals [13,16].
This study aimed to describe and characterize global
collaborative patterns with regard to the conduct of meta-
analyses of randomized trials published over the past three
decades in high impact factor medical journals, by applying
techniques from social network analysis.
Methods
Design and sample
In December 2012, we searched for reports of meta-
analyses of randomized trials that were indexed in PubMed
and published in one of the top seven high impact general
medical journals, as identified in 2011, based on an impact
factor of at least 10 (subject categories ‘Medicine, General &
Internal’ of Journal Citation Reports, Thomson Reuters):
The New England Journal of Medicine (NEJM), The Lancet,
the British Medical Journal (BMJ), the Journal of theAmerican Medical Association (JAMA), Annals of Internal
Medicine, Archives of Internal Medicine (now renamed
JAMA Internal Medicine) and PLoS Medicine. Specifically,
the following terms were used for PubMed: (‘meta-analy-
sis’[Publication Type] OR ‘meta-analysis as topic’[MeSH
Terms] OR ‘meta-analysis’[All Fields]) AND (‘randomized
controlled trial’[Publication Type] OR ‘randomized con-
trolled trials as topic’[MeSH Terms] OR ‘randomized con-
trolled trial’[All Fields]) AND (‘Lancet’[Journal] OR ‘N Engl
J Med’[Journal] OR ‘JAMA’[Journal] OR ‘Br Med J’[Journal]
OR ‘Br Med J (Clin Res Ed)’[Journal] OR ‘BMJ’[Journal] OR
‘PLoS Med’[Journal] OR ‘Ann Intern Med’[Journal] OR
‘Arch Intern Med’[Journal]) AND (hasabstract[text] AND
‘humans’[MeSH Terms]). We also performed complemen-
tary hand-searches and reviewed references of identified
eligible reports to identify additional meta-analyses.
We included two types of articles from the eligible
journals: original research reports and reviews (both in-
corporating meta-analyses of randomized trials). Editorials,
commentaries, and other opinion articles were excluded.
We also excluded conceptual papers, literature (narrative)
reviews, reviews of reviews, meta-analysis of observational
studies not considering randomized trials, single random-
ized trials, and other study designs (such as cost-effective-
ness analyses and epidemiological studies).
For the purposes of this study, we selected all articles
published in English and indexed in PubMed between
January 1985 and December 2012. One researcher with
expertise in evidence synthesis (FC-L) screened the titles
and abstracts, and identified all potentially eligible articles.
The same researcher excluded the articles not meeting the
pre-specified criteria.
Data extraction
For each included paper, we extracted information on
the year of publication, the journal title, and the authors’
names, institutional affiliation(s), and country of origin.
This information was downloaded online through the
Science Citation Index-Expanded (SCI-E) Web of Know-
ledge platform version 5, in April 2013. The Web of Know-
ledge platform is a database that contains all the above
information, including the full addresses of all authors of
every paper. We also used the SCI-E to determine the ex-
tent to which each study had been cited in the scientific
peer-review literature using the ‘times cited’ number (that
is, the number of times a publication has been cited by
other publications). A process of standardization was con-
ducted to bring together the different names of a particular
author or institution. Specifically, one researcher (AA-A)
checked the names by which an individual author appeared
in two or more different forms (for example, ‘Gordon
Guyatt’ or ‘Gordon H Guyatt’), using coincidence in that
author’s place(s) of work as the basic criterion for nor-
malization (for example, McMaster University, Canada).
Figure 1 Selection of publications. Flow chart.
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to match the name recorded in public directories of insti-
tutions. Similarly, given that institutional names in many
records included two or more institutions (for example,
university hospitals, research centers and academic institu-
tions), we proceeded to distinguish between these names by
recording all variations of any individual macroinstitution
as could be identified for each bibliographic record (for ex-
ample, for the institutional address ‘Reproductive Medicine
Unit, Department of Obstetrics & Gynaecology, University
of Adelaide, Queen Elizabeth Hospital, Australia’, the
standardization approach was to present ‘University of
Adelaide, Australia’ separately from ‘Queen Elizabeth
Hospital, Australia’). With all this information, we con-
structed a Microsoft Access database.
Data analysis
In this paper, we use the term ‘co-authorship’ to refer to
joint authorship of a scientific paper by at least two indi-
viduals, and the term ‘institutional collaboration’ to refer
to joint authorship by different institutions. ‘Intensity of
collaboration or threshold’ refers to the number used to
form clusters of authors and institutions (that is, the fre-
quency of co-authorship between pairs of authors or of
collaboration between institutions), and reflects a criterion
to label identifiable clusters as research groups. Collabor-
ation between authors (or institutions) was portrayed by
calculating the number of papers, names, signatures and
collaborations, the index of signatures per paper or collab-
oration index (which is the mean number of signatures
per paper), and the index of authors per paper (mean
number of authors per paper, considering only the different
authors). A summary box with definitions of each of
the measurements of collaboration is provided in the
supplementary material (see Additional file 1: ‘Definitions
of collaborative measurements’).
To construct co-authorship networks, we identified all
combinations of pairs of authors for each paper. The
number of co-authorships for each paper is related to
the number of authors as is equal to
m!
m−nð Þ!n! ;
where m is the number of individual authors and n the
number of elements in the groups constructed. Once
co-authorship was quantified, we further established an
a posteriori threshold of two or more collaborations be-
tween pairs of authors, in order to reduce the number of
nodes and links that would prevent a clear view of the
network, and thus center the analysis on the more intense
co-authorship relationships. The same approach was ap-
plied to institutional and country authorship to construct
the network of collaborations, although in this case, weapplied an a posteriori threshold of three or more papers
signed in co-authorship. The productivity and patterns of
collaboration by author, institution and country were
analyzed.
We used PAJEK [17], a software package for large
network analysis that is free for non-commercial use,
to analyze indicators and construct social networks.
Results
Number of meta-analyses
The PubMed search generated 804 records. Following
screening of abstracts and full text articles, 724 publications
were retained, and 12 additional publications were added
from complementary searches of reference lists, thereby
yielding a final sample of 736 included meta-analyses. The
process of study selection is presented in Figure 1.
General characteristics of the sample
The BMJ published the largest number of articles (n = 289;
39%), followed by The Lancet (n = 132; 18%), JAMA (n =
113; 15%) and the Archives of Internal Medicine (n = 112;
15%). Overall, 736 meta-analyses received 130,644 citations,
of which 37,930 citations (29%) corresponded to BMJ, 34
911(27%) to The Lancet and 25,273 (19%) to JAMA. The
number of publications increased exponentially over the
study period (Table 1). Approximately three-quarters of
the meta-analyses were reported during the most recent
decade.
The included meta-analyses had a median of 5 authors,
although 41 (6%) were single authored (Table 1). More
than a quarter (214 [29%]) of the first authors were
from the USA, with three countries (the USA, the UK
and Canada) accounting for more than two-thirds of
the meta-analyses published during the period of analysis
(Table 1).
Table 1 General characteristics of the sample of study
Characteristic Number (%)
Total number of articles 736 (100)
Articles per journala
BMJ 289 (39.3)
The Lancet 132 (17.9)
JAMA 113 (15.3)
Arch Intern Med 112 (15.2)
Ann Intern Med 70 (9.5)
New Engl J Med 13 (1.8)
PLoS Med 7 (0.9)
Citations per journalb
BMJ 37,930 (29.0)
The Lancet 34,911 (26.7)
JAMA 25,273 (19.3)
Ann Intern Med 13,381 (10.2)
Arch Intern Med 11,945 (9.1)
New Engl J Med 6,992 (5.3)
PLoS Med 212 (0.1)
Articles per period of publication
1985 to 1989 3 (0.4)
1990 to 1994 53 (7.2)
1995 to 1999 140 (19.0)
2000 to 2004 166 (22.6)
2005 to 2009 231 (31.4)
2010 to 2012 143 (19.4)
Country of publication (first author)c
USA 214 (29.1)
UK 207 (28.1)
Canada 94 (12.8)
Australia 36 (4.9)
Switzerland 26 (3.5)
France 26 (3.5)
Denmark 20 (2.7)
Italy 20 (2.7)
Number of authors per paper
1 41 (5.6)
2 to 3 166 (22.5)
4 to 6 297 (40.3)
> 7 232 (31.5)
aPLOS Medicine has been published weekly online since 19 October 2004.
bInformation refers to the total citations received by all the papers published
in a given journal (for example, 289 papers published in BMJ received a total
of 37,930 citations).
cInformation was incomplete for some records. We used country data of the
first author in 704 out of 736 papers, while for 32 papers this information was
retrieved from the correspondence address.
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Overall, 3,178 authors, 891 institutions and 51 countries
worldwide were involved in the sample of articles. We
identified 64 authors who published 5 or more papers
(Table 2). The most prolific authors were Lau (15 papers),
Guyatt (14), Peto (13), Yusuf (12), Cook (11) and Jüni (11).
Many of the most prolific authors are affiliated with only a
few academic institutions and/or medical centers; six are
affiliated with the University of Oxford (Peto, Collins,
Clarke, Baigent, Gray and Rothwell), five are affiliated
with McMaster University (Guyatt, Yusuf, Cook, Douketis,
and Eikelboom) and five are affiliated with the University of
Bern and/or the Inselspital – Bern University Hospital
(Jüni, Trelle, Egger, Reichenbach and Nüesch). Apply-
ing a threshold of 2 or more papers published as co-
authors (Figures 2, 3, 4, 5, 6, 7), we identified 82 clusters
of authors. Of these, 12 were identified as major co-
authorship groups (1 with 55 members, 1 with 54 mem-
bers, 1 with 27 members, 1 with 15, 4 with 14 members,
3 with 11 members, 1 with 10 members, 1 with 8 mem-
bers, 5 with 7 members, 5 with 6 members and 3 with 5
members).
Institutional productivity was headed by McMaster
University (49 papers), University of Oxford (48 papers)
and Harvard University (36 papers) (Table 3). Next came
some of their affiliated hospitals or medical centers
(Brigham and Women’s Hospital and the Radcliffe In-
firmary, with 32 and 30, respectively). Applying a col-
laboration threshold of at least 3 papers signed with
inter-institutional collaboration, we identified 19 clusters
comprising a total of 120 institutions (Figures 8 and 9). Of
these, the most important institutional cluster comprised
76 members.
The productivity ranking for countries with respect to
the number of papers (Table 4) was headed by the USA
(310 papers), the UK (297 papers) and Canada (143 papers).
After these countries came Australia (70 papers), and Italy
and the Netherlands (57 papers each). The USA and the
UK also headed the list of the number of different countries
with which they had collaborated, as well as the total
number of collaborations. Figure 10 shows a visual repre-
sentation of the collaborative network between countries,
in which we can see the relationships of some with respect
to others and the position that each occupies in the
network as a whole.
The 75 most cited articles by number of citations are
listed in the supplementary material (see Additional file 2:
‘List of most cited meta-analyses’). Heavily cited meta-
analyses include randomized trials examining the health
effects of pharmacological interventions in cardiology and
oncology (for example, antithrombotic trials, anti-platelet
trials, antihypertensive trials, lipid-lowering trials, chemo-
therapy for diverse cancers such as breast cancer, lung
cancer, or head and neck cancers).
Table 2 Ranking of most prolific authors (five or more papers) and their collaborative patterns
Author Primary affiliation at
the time of publication
Year of first
eligible paper
Total
papers, n
Signatures, n Collaborations, n Main collaborators
(number of papers)
Lau, Joseph Brown University, USAa 1992 15 90 54 Chalmers TC and Ioannidis
JPA (5)
Guyatt, Gordon H McMaster University,
Canada
1996 14 104 76 Cook DJ (5)
Peto, Richard University of Oxford, UK 1991 13 124 75 Collins R (8)
Yusuf, Salim McMaster University,
Canada
1989 12 83 54 Collins R, Eikelboom JW, Mehta
SR and Pogue J (3)
Cook, Deborah J McMaster University,
Canada
1995 11 71 49 Guyatt GH (5)
Jüni, Peter University of Bern,
Switzerland
1996 11 124 59 Reichenbach S (8)
Collins, Rory University of Oxford, UK 1991 9 78 45 Peto R (8)
Trelle, Sven University of Bern,
Switzerland
2007 9 103 67 Jüni P and Reichenbach S (7)
Bucher, Heiner C University Hospital
Basel, Switzerland
1996 8 60 41 Guyatt GH (4)
Egger, Mathias University of Bern,
Switzerland
2001 8 65 49 Jüni P, Reichenbach S and
Trelle S (3)
Gluud, Christian Copenhagen University
Hospital, Denmark
2001 8 40 21 Wetterslev J (3)
Gøtzsche, Peter C The Nordic Cochrane
Centre, Denmark
1995 8 27 17 Johansen HK (3)
Jackson, Jeffrey L Zablocki VA Medical
Center, USA
1997 8 33 23 Browning R and O’Malley
Patrick G (2)
Law, Malcolm R Queen Mary University
of London, UK
1991 8 24 7 Wald NJ (8)
Reichenbach, Stephan University of Bern,
Switzerland
2004 8 81 44 Jüni P (8)
Sutton, Alex J University of Leicester, UK 2003 8 40 28 Cooper NJ (3)
Suttorp, Maarten J St Antonius Hospital,
the Netherlands
2003 8 120 61 Maglione M, Mojica WA, Morton
SC and Shekelle PG (5)
Wald, Nicholas J Queen Mary University
of London, UK
1991 8 24 7 Law MR (8)
Clarke, Michael University of Oxford, UK 1994 7 83 67 Peto R (4)
Furberg, Curt D Wake Forest University
School of Medicine, USA
1989 7 36 20 Loke YK, Psaty BM and
Singh S (3)
Baigent, Colin University of Oxford, UK 1996 6 50 26 Collins R and Peto R (5)
Boersma, Eric Erasmus Medical Center,
the Netherlands
2001 6 74 63 Califf RM, Serruys P, Simes J,
Simoons ML and Topol EJ (2)
Boissel, Jean-Pierre Université Claude Bernard
Lyon 1, France
1992 6 42 26 Fagard RH and Gueyffier F (3)
Chalmers, Thomas C Tufts Medical Center,
Tufts University, USA
1990 6 31 16 Lau J (5)
Douketis, James D McMaster University,
Canada
2000 6 32 25 Crowther MA (2)
Ebrahim, Shah London School of
Hygiene and Tropical
Medicine, UK
1997 6 70 60 Smith GD (4)
Ioannidis, John PA Stanford University, USA 1995 6 32 17 Lau J (5)
Khan, Khalid S Queen Mary University
of London, UK
1996 6 39 27 Bhattacharya S, Champaneria R,
Cooper K, Jolly K and Middleton
LJ (2)
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Table 2 Ranking of most prolific authors (five or more papers) and their collaborative patterns (Continued)
Klassen, Terry P University of Manitoba,
Canada
1996 6 48 36 Moher D (3)
Loke, Yoon K University of East Anglia,
UK
2000 6 18 7 Singh S (4)
McAlister, Finlay A University of Alberta,
Canada
2001 6 30 23 Armstrong PW (2)
Moher, David Ottawa Hospital Research
Institute, Canada
1996 6 52 42 Klassen TP (3)
Roberts, Ian London School of
Hygiene and Tropical
Medicine, UK
1996 6 18 12 All co-authorship (1)
Sattar, Naveed University of Glasgow,
UK
2009 6 91 58 Ray KK and Seshasai SRK (5)
Shekelle, Paul G Rand Corporation, USA 2003 6 57 29 Maglione M, Mojica WA, Morton
SC and Suttorp MJ (5)
Stone, Gregg W Columbia University
Medical Center, USA
2005 6 120 77 Leon MB (4)
Tognoni, Gianni Consorzio Mario Negri
Sud, Italy
1993 6 78 69 Marchioli R, Marfisi RM and
Roncaglioni MC (2)
Topol, Eric J Scripps Translational
Science Institute, USA
1991 6 44 33 Boersma E, Califf RM, Simoons
ML, Tcheng JE and Van de
Werf F (2)
Bischoff Ferrari, Heike A University Hospital
Zurich, Switzerland
2004 5 48 26 Dawson Hughes B, Staehelin
HB, Willett WC and Wong
JB (4)
Briel, Matthias University Hospital
Basel, Switzerland
2006 5 51 43 Bucher HC (3)
Eikelboom, John W McMaster University,
Canada
2000 5 19 10 Yusuf S (3)
Ernst, Edzard University of Exeter, UK 1995 5 18 11 White AR (3)
Fagard, Robert H University of Leuven,
Belgium
1997 5 51 36 Boissel JP and Gueyffier F (3)
Fergusson, Dean Ottawa Hospital Research
Institute, Canada
1998 5 33 22 Hutton B (3)
Glasziou, Paul Bond University, Australia 1993 5 26 21 All co-authorship (1)
Godwin, Jon Glasgow Caledonian
University, UK
1995 5 52 38 Peto R (4)
Gray, Richard University of Oxford, UK 2001 5 48 36 Clarke M and Peto R (3)
Hennekens, Charles H Florida Atlantic University,
USA
1995 5 28 19 Hebert, PR (4)
Leibovici, Leonard Rabin Medical Center,
Israel
2003 5 22 12 Paul M (5)
Maglione, Margaret Rand Corporation, USA 2003 5 49 22 Mojica WA, Morton SC, Shekelle
PG and Suttorp MJ (5)
Mojica, Walter A Rand Corporation, USA 2003 5 49 22 Maglione M, Morton SC, Shekelle
PG, and Suttorp MJ (5)
Morton, Sally C University of Pittsburgh,
USA
2003 5 49 22 Maglione M, Mojica WA, Shekelle
PG and Suttorp MJ (5)
Nüesch, Eveline University of Bern,
Switzerland
2009 5 35 16 Jüni P (5)
Paul, Mical Rabin Medical Center,
Beilinson Hospital, Israel
2003 5 22 12 Leibovici L (5)
Pignon, Jean-Pierre Institut Gustave-Roussy,
France
1999 5 53 46 Bourhis J and Michiels S (2)
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Pocock, Stuart J London School of
Hygiene and Tropical
Medicine, UK
1995 5 67 54 Boissel JP, Boutitie F, Fagard RH,
Gueyffier F, Hamm CW, Hueb WA,
King SB and Rodríguez A (2)
Ray, Kausik K St George’s University
of London, UK
2009 5 73 49 Saltar N and Seshasai SRK (5)
Rothwell, Peter M University of Oxford, UK 2003 5 36 19 Belch JFF and Meade TW (3)
Seshasai, Sreenivasa RK University of Cambridge,
UK
2009 5 73 49 Ray KK and SN (5)
Simes, John National Health and
Medical Research Council
Clinical Trials Centre,
Australia
2002 5 53 36 Baigent C, Blackwell L, Collins R,
Keech A and Peto R (3)
Smith, George Davey University of Bristol, UK 1993 5 63 54 Ebrahim S (4)
Torgerson, David J University of York, UK 1999 5 46 39 Adamson SJ and Bell Syer
SEM (2)
Wetterslev, Jorn Copenhagen University
Hospital, Denmark
2007 5 28 15 Gluud C (3)
Wilt, Timothy J Minneapolis VA Center
for Chronic Disease
Outcomes Research,
USA
1998 5 40 32 MacDonald R (4)
aJoseph Lau was based at Tufts University Medical Center in Boston (USA) until 2012, and the institutional networks represent this fact.
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Generally, the visibility and recognition of scientific re-
search activities benefits from increasing collaborative
research [18]. Research collaboration plays an important
role in science, policy and medicine [19,20]. Research
collaboration in the ‘Big Science’ era involves addressingFigure 2 Co-authorship networks. Most productive cluster of authors, apimportant and relevant research questions that require a
complex construction of multi-disciplinary teams of scien-
tists and researchers, large-scale scientific structures, bud-
gets of an unprecedented scale, and widespread sharing of
scientific knowledge and data. Thus, meta-analysis can be
considered a good example of ‘Big Science’ in medicineplying a threshold of two or more papers signed in co-authorship.
Figure 3 Co-authorship networks. Second most productive cluster of authors, applying a threshold of two or more papers signed in co-authorship.
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synthesis is the application, in practice, of the principle
that science is cumulative [22,23]. An obvious manifest-
ation of this is the observed trend of 75 new randomized
trials and 11 new systematic reviews being published
daily, with a plateau in this growth not yet reached [24].Figure 4 Co-authorship networks. Main clusters of authors (≥ 15 membersTherefore, promoting research collaboration in evidence
synthesis is able to strengthen research activity, productiv-
ity and impact.
In general, we found a strong clustering of papers
published in two British journals (BMJ and The Lancet
accounted for 57% of meta-analyses), in contrast to other), applying a threshold of two or more papers signed in co-authorship.
Figure 5 Co-authorship networks. Main clusters of authors (≤ 14 members), applying a threshold of two or more papers signed in co-authorship.
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sented less than 2%). We hypothesized that these different
findings between journals may potentially reflect an edi-
torial policy and/or preference, with the BMJ, The Lancet
and JAMA journals specifically being more interested inFigure 6 Co-authorship networks. Main clusters of authors (≤ 11 membersand/or promoting the publication of high-quality quantita-
tive evidence synthesis.
Perhaps a relevant finding is that collaborative networks
are expanding in multiple regions, revealing a discernable
and well-established scientific community, with the most), applying a threshold of two or more papers signed in co-authorship.
Figure 7 Co-authorship networks. Main clusters of authors (≤ 6 members), applying a threshold of two or more papers signed in co-authorship.
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number of collaborations. As might be expected, the
scientific community captured by the networks is centered
on a nucleus of scientists and researchers from academia,
medical centers and health research institutes from
western high-income countries (North America, Western
Europe and Australia/Oceania). Specifically, the most in-
tense global collaborations took place between authors
and institutions from the USA, the UK and Canada. How-
ever, although these three countries lead in the number of
published high impact meta-analyses, the efforts during
the period of study were global, with publications from
authors and institutions in more than 50 different coun-
tries. Cultural links may have historically benefited some
countries through alliances with nations and regions that
speak the same language (as may be the case for the UK
through alliances with Commonwealth countries that speak
English) and have adopted similar scientific and research
structures [25]. However, there is a clear over-representa-
tion of scientists based in western high-income countries,
and the limited participation of low and middle income-
based researchers could warrant further pragmatic action.
Given that research resources and funding are often re-
stricted, it is the responsibility of the scientific commu-
nity to utilize the resources available most efficiently when
exploring research priorities to afford the health needs of
the population, stimulating north–south and west–east
collaborations where possible. In fact, these results are
consistent with those reported by Uthman et al. [26], who
assessed the characteristics of the 100 most frequently
cited meta-analysis related articles. Although the scope ofour research is definitely different from that paper, those
authors also showed that the USA, the UK and Canada
have taken leadership in the production of citation papers,
but no first author from low or middle income countries
led one of the most cited papers.
The maps of scientific partnership show that authors
who are ‘leaders’ and thus who may contribute collab-
oration, have more frequent and intense collaboration
between other authors and institutions from different
countries. The study also identifies highly cohesive cluster
networks and provides considerable information on the
structure that can be put to various purposes, such as
funding agencies designing strategies for future scien-
tific collaboration, agencies such as the World Health
Organization promoting a global coordinated agenda for
perceived high priority clinical topics, and sharing of reli-
able and innovative methodologies that can be linked to
world-class educational and training opportunities.
There are several possible explanations for our findings.
The use of modern communication and information tech-
nologies, especially the Internet, has diminished the role
of geographical and territorial boundaries in the access
and transmissibility of information [27]. This has enabled
scientists, and particularly systematic reviewers, closer
internalization of research and collaboration. Similarly, the
creation of some international collaborations, including
those conducting clinical trials, may have settled the
groundwork for the subsequent realization of collaborative
meta-analyses that may have a clear scientific and clinical
impact. For example, according to SCI-E, the most cited
meta-analysis article has received more than 2,500 citations;
Table 3 Ranking of most prolific institutions (≥ 10 papers) and their collaborative patterns
Institution, country Total
papers, n
Signatures,
n
Institutional
collaborations (with
different institutions), n
Institutional collaborations
in same country
(domestic institutions), n
Institutional
collaborations from
different countries, n
Main institutional collaborator
(number of papers)
Different
collaborative
countries, n
McMaster
University, Canada
49 216 109 31 78 University of Toronto, Canada (10) 19
University of Oxford, UK 48 226 123 39 84 Radcliffe Infirmary, UK (13) 20
Harvard University, USA 36 210 104 47 57 Brigham and Women’s Hospital, USA (23) 16
Brigham and Women’s
Hospital, USA
32 207 102 46 56 Harvard University, USA (23) 17
Radcliffe Infirmary, UK 30 96 46 14 32 University of Oxford, UK (13) 11
University of London, UK 29 207 125 34 91 University of Bristol, UK; University of
Edinburgh, UK and University of Oxford, UK (5)
22
Copenhagen University
Hospital, Denmark
28 169 93 8 85 Azienda Ospedaliera San Camillo-Forlanini, Italy;
Université Paris V - René Descartes, France
and University of Copenhagen, Denmark (4)
20
University of
Toronto, Canada
27 123 55 23 32 McMaster University, Canada and Sunnybrook
Health Science Center, Canada (4)
12
University of
Sydney, Australia
23 120 70 14 56 National Health and Medical
Research Council (NHMRC), Australia (6)
15
University of
Birmingham, UK
22 80 51 26 25 Queen Mary, University of London,
UK and University of Aberdeen, UK
(3) 11
University of Bristol, UK 22 141 96 33 63 University of London, UK (5) 21
University of
Alberta, Canada
20 94 57 14 43 Institute of Health Economics, Canada
and University of Calgary, Canada (4)
15
University College
London, UK
19 123 88 33 55 London School of Hygiene & Tropical
Medicine, UK and Royal Free Hospital, UK (4)
20
University Hospital
Basel, Switzerland
18 185 113 9 104 Inselspital, Switzerland (5) 20
Mayo Clinic, USA 18 157 130 35 95 University of Texas Medical
School at Houston, USA (3)
23
University of Glasgow, UK 17 124 85 32 53 University of Cambridge, UK (4) 14
Erasmus MC University
Medical Center Rotterdam,
the Netherlands
17 145 106 8 98 Duke Clinical Research Institute (DCRI),
USA and University of Sydney, Australia (3)
23
Cleveland Clinic, UK 16 75 51 11 40 Duke Clinical Research Institute (DCRI),
USA and University of Sydney, Australia (3)
14
The University of York, UK 16 64 44 26 18 University of Leeds, UK (3) 8
University of
Bern, Switzerland
16 128 72 8 64 Inselspital, Switzerland (11) 16
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Table 3 Ranking of most prolific institutions (≥ 10 papers) and their collaborative patterns (Continued)
Medical Research Council’s
Clinical Trials Unit, UK
16 81 59 25 34 University of Leicester, UK (3) 14
Johns Hopkins University,
USA
15 58 42 18 24 University Hospital Basel, Switzerland (2) 11
Instituto di Ricerche
Farmacologiche Mario
Negri, Italy
15 85 63 9 54 University of Sydney, Australia (3) 14
Hamilton Health
Sciences, Canada
14 64 37 5 32 McMaster University, Canada (9) 11
University of
Calgary, Canada
14 62 35 17 18 University of Alberta, Canada (4) 10
Tufts University, USA 14 79 45 14 31 Tufts Medical Center, USA (6) 13
University of California,
San Francisco, USA
14 77 56 24 32 San Francisco VA Medical Center, USA (3) 16
University of Aberdeen, UK 13 73 50 25 25 NHS Grampian, UK (5) 11
Sunnybrook Health Science
Center, Canada
13 83 45 17 28 University of Toronto, Canada (10) 9
University of Ottawa,
Canada
13 70 40 16 24 Children’s Hospital of Eastern Ontario,
Canada; McMaster University, Canada; Ottawa
Hospital Research Institute (OHRI), Canada;
University of Manitoba, Canada and University
of Toronto, Canada (3)
13
Wake Forest
University, USA
12 55 31 17 14 University of East Anglia, UK and
University of Washington, USA (4)
7
Inselspital, Switzerland 12 119 67 8 59 University of Bern, Switzerland (11) 16
University of
Washington, USA
12 44 25 12 13 VA Puget Sound Health Care System,
USA and Wake Forest University, USA (4)
8
University of Edinburgh, UK 12 106 66 30 36 University of London, UK (5) 17
Technical University
of Munich, Germany
11 110 63 3 60 Columbia University Medical
Center (CUMC), USA (4)
17
Queen Mary, University
of London, UK
11 46 31 8 23 University of Birmingham, UK (3) 9
Tufts Medical Center, USA 11 41 16 8 8 Tufts University, USA (6) 3
London School of
Hygiene & Tropical
Medicine, UK
11 106 86 15 71 University College London, UK (4) 25
University of
Pittsburgh, USA
11 64 51 16 35 Erasmus MC University Medical Center
Rotterdam, the Netherlands and
Ohio State University, USA (2)
12
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Figure 8 Institutional networks. Most productive cluster of institutions applying a threshold of three or more papers signed in co-authorship.
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oration [28] that contributed to determine the protective
effects of anti-platelet therapy (such as low dose aspirin)
for patients at high risk of occlusive vascular events.
Analyses of the Oxford-based Early Breast Cancer Trialists
Collaborative Group (EBCTCG) provided breakthrough
examples of complete pictures of the evidence on theFigure 9 Institutional networks. Other relevant clusters of institutions aplong-term effects of various therapies on early breast
cancer [29-31].
Collaborative networks, an important form of social
network analysis, have been intensively studied in many
scientific disciplines, including biology, physics, medicine
and economics [13,16,32-36]. To our knowledge, no study
has previously described and characterized the globalplying a threshold of three or more papers signed in co-authorship.
Table 4 Productivity and patterns of collaboration by countries
Country Total
papers, n
Papers per million
inhabitants, n
Collaborations, n Distinct countries
of collaborations, n
Main collaborator(s)
(number of collaborations)
USA 310 0.99 428 43 UK (63)
UK 297 4.73 380 44 USA (69)
Canada 143 4.15 200 29 USA (53)
Australia 70 3.14 165 30 UK (30)
Italy 57 0.94 205 29 USA (34)
The Netherlands 57 3.41 173 27 USA (27)
France 51 0.78 159 27 USA (26)
Germany 50 0.61 164 32 USA (30)
Switzerland 47 5.94 177 35 USA (25)
Denmark 41 7.36 124 28 UK (18)
Belgium 23 2.09 92 23 UK (14)
Sweden 21 2.22 69 14 USA (13)
Spain 19 0.41 76 28 USA (8)
Norway 14 2.83 56 20 UK and USA (11)
Japan 13 0.10 51 21 USA (9)
New Zealand 13 2.95 24 11 UK (8)
Finlad 11 2.04 43 14 Australia and USA (7)
Brazil 9 0.05 40 16 UK and USA (5)
Greece 8 0.71 12 5 UK and USA (4)
Israel 8 1.03 7 5 USA (3)
Ireland 6 1.31 24 14 UK (5)
China 6 0.00 10 7 USA (4)
South Africa 6 0.12 23 16 USA (4)
Argentina 5 0.12 24 13 Brazil, Switzerland, UK and USA (3)
Czech Republic 5 0.48 42 18 UK and USA (5)
Poland 5 0.13 23 13 UK (4)
South Korea 5 0.10 31 13 USA (4)
Austria 4 0.47 9 6 Germany (3)
Thailand 4 0.06 10 10 All countries (1)
Chile 3 0.17 10 8 Canada and USA (2)
India 3 0.00 2 2 Australia and UK (1)
Portugal 3 0.28 1 1 Canada (1)
Taiwan 3 0.13 3 3 Denmark, UK and USA (1)
Costa Rica 2 0.42 8 6 Canada and USA (2)
Hungary 2 0.20 16 14 UK and USA (2)
Pakistan 2 0.01 2 1 UK (2)
Russia 2 0.01 18 14 Belgium, Denmark, Germany, and UK (2)
Saudi Arabia 2 0.07 7 6 UK (2)
Serbia and Montenegro 2 0.28 4 2 Denmark and Italy (2)
Turkey 2 0.03 13 9 Australia, Canada, Switzerland and USA (2)
Colombia 1 0.02 6 6 All countries (1)
Cuba 1 0.09 5 5 All countries (1)
Gabon 1 0.65 10 10 All countries (1)
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Table 4 Productivity and patterns of collaboration by countries (Continued)
Ghana 1 0.04 10 10 All countries (1)
Latvia 1 0.49 12 12 All countries (1)
Mexico 1 0.01 1 1 USA (1)
Morocco 1 0.03 10 10 All countries (1)
Mozambique 1 0.04 10 10 All countries (1)
Republic of Malawi 1 0.07 1 1 UK (1)
Singapore 1 0.19 0 0 -
Tanzania 1 0.02 10 10 All countries (1)
Note: Country inhabitants (year 2011) were obtained from the World Bank.
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analyses of randomized trials. Very few studies have
reviewed evidence synthesis for decision-making using
a research collaboration approach [35,36], and although not
directly comparable with our analysis, there are aspects
worthy of comment. A recent paper by Wagstaff and
Culyer [35] examined four decades of health economics
research. They compared authors, institutions, countries
and journals in terms of the volume of publications in the
US, the UK and Canada; Harvard University, the World
Bank and the MIT emerged at the top on a variety of mea-
sures. Previously, Greenberg et al. [36] conducted a review
of cost-effectiveness analyses of the English-language
articles indexed in PubMed since 2006, and observed
that the most prolific authors were affiliated with renowned
US institutions in the USA (for example, Harvard University,Figure 10 Global collaborative network between countries. Note: Nod
are proportional to the number of collaborations.Stanford University and Tufts University, and their affili-
ated hospitals).
There are several limitations to our study. First, although
the scientific production analysed has been drawn from an
exhaustive analysis of the literature, it is possible that the
search missed some relevant articles. Furthermore, some
reports were published in journals without being indexed
as meta-analyses, making them difficult to identify. The
analyses inevitably represent an initial investigation, and a
more detailed exploration is also needed. In addition, we
restricted our analysis to meta-analyses that considered
randomized trials as the primary source of clinical evidence,
and therefore there may be scientists and researchers (or
institutions) who do not appear because their papers are
not reflected in the collaborative networks (for example,
genetic epidemiology). It would be interesting to exploree sizes are proportional to the number of papers and line thicknesses
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vational research, descriptive epidemiology, molecular
genetics, non-clinical studies) resulted in similar results to
those reported here. Our analysis was also limited in scope,
focusing only on original research and reviews articles.
Undoubtedly, there are other important reports (for
example, methodological [37-39] and conceptual papers
[6,40,41]) that also merit consideration. Second, we ex-
cluded the Cochrane Library, specifically, the Cochrane
Database of Systematic Reviews, a major source of sys-
tematic reviews. However, to date its impact factor is
smaller than that of any of the included journals. Given
the dynamic nature of the field, other opportunities for
further research include examining the evolution of the
identified networks over time (for example, by means of
longitudinal analysis) also considering papers published in
multi-disciplinary journals or those included in journals
belonging to other categories.
Additionally, there were no further inquiries or attempts
to verify the quality of reporting of the meta-analyses in
our sample. Previous research [42] has addressed this issue,
pointing out that some of the meta-analyses published in
leading medical journals have important methodological
limitations. Third, as in many bibliometric analyses, the im-
portance of normalizing the names of scientists, researchers
and their institutions is fundamental to avoiding potential
errors caused in recognizing variations in the name of a sin-
gle author. Nevertheless, we conducted a careful manual
validation of the bibliographic references to avoid these po-
tential errors. In the case of authors, the criterion followed
with two or more variants of a name or surname was to
check the coincidence of the different variants with the
workplace. As discussed elsewhere [34], this procedure does
not assure complete certainty. It does not take into account
possible changes in the author’s workplace, nor does it
avoid the problem where the same bibliographic name
refers to the scientific production of two or more authors,
although the fact that a single field and a short chrono-
logic period were being analyzed helped to minimize this
kind of error. For institutional names, the main problem is
that the same name frequently applies to two or more
institutions, something that is common for authors who
work in institutes or hospitals connected to universities.
In such cases, we opted to assign as many names to the
macroinstitutions as could be identified. Although this
resulted in the problem of multiplying the number of
institutions in the recount, it was necessary in order to
avoid losing information concerning the macroinstitutions
occurring in second place or later in the list of names. The
same criterion of multiplying the names was used in the
case of the institutes and other research organizations,
sometimes administratively dependent on one macroinsti-
tution, the result being that a ‘fictitious’ inter-institutional
collaboration may have been obtained.Conclusions
Our study identified the most significant collaborative
networks of authors, institutions and countries publishing
meta-analyses of randomized trials in high impact medical
journals. This information may be used to strengthen
scientific capacity for global collaboration and help to
build a cooperative scientific agenda for future research of
excellence in the field of clinical evidence synthesis in a
manner similar to how some international clinical trial
collaborations have developed. We hope that this analysis
will be useful as policy makers, researchers and institutions
look to the future.
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